Skip Navigation
Genetics Home Reference: your guide to understanding genetic conditions About   Site Map   Contact Us
 
Home A service of the U.S. National Library of Medicine®
 
 
Printer-friendly version
Essential thrombocythemia

Essential thrombocythemia

Reviewed December 2011

What is essential thrombocythemia?

Essential thrombocythemia is a condition characterized by an increased number of platelets (thrombocythemia). Platelets (thrombocytes) are the blood cells involved in blood clotting.

Abnormal blood clotting (thrombosis) is common in people with essential thrombocythemia and causes many signs and symptoms of this condition; however, some people with essential thrombocythemia have no signs or symptoms. Clots that block blood flow to the brain can cause strokes or temporary stroke-like episodes known as transient ischemic attacks. Thrombosis in the legs can cause leg pain, swelling, or both. In addition, clots can travel to the lungs (pulmonary embolism), blocking blood flow in the lungs and causing chest pain and difficulty breathing (dyspnea).

Another problem in essential thrombocythemia is abnormal bleeding, which occurs more often in people with a very high number of platelets. It is thought that bleeding occurs because a specific protein in the blood that helps with clotting is reduced, although why the protein is reduced is unclear. Affected people may have nosebleeds, bleeding gums, or bleeding in the gastrointestinal tract.

Other signs and symptoms of essential thrombocythemia include an enlarged spleen (splenomegaly); weakness; headaches; or a sensation in the skin of burning, tingling, or prickling. Some people with essential thrombocythemia have episodes of severe pain, redness, and swelling (erythromelalgia), which commonly occur in the hands and feet.

How common is essential thrombocythemia?

Essential thrombocythemia affects an estimated 1 to 24 per 1 million people worldwide.

What genes are related to essential thrombocythemia?

Mutations in the JAK2, MPL, THPO, and TET2 genes are associated with essential thrombocythemia. The TET2 gene provides instructions for making a protein whose function is unknown. The JAK2, MPL, and THPO genes provide instructions for making proteins that promote the growth and division (proliferation) of blood cells.

The proteins produced from the JAK2, MPL, and THPO genes are part of a signaling pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the cell's nucleus. The THPO gene provides instructions for making the thrombopoietin protein, and the MPL gene provides instructions for making the thrombopoietin receptor protein. These proteins work together to turn on (activate) the JAK2 protein and the JAK/STAT pathway. Through the JAK/STAT pathway, these proteins promote the proliferation of blood cells, particularly platelets and their precursor cells, megakaryocytes.

Mutations in the JAK2, MPL, and THPO genes that are associated with essential thrombocythemia lead to overactivation of the JAK/STAT pathway. The abnormal activation of JAK/STAT signaling leads to overproduction of megakaryocytes, which results in an increased number of platelets. Excess platelets can cause thrombosis, which leads to many signs and symptoms of essential thrombocythemia.

Although mutations in the TET2 gene have been found in people with essential thrombocythemia, it is unclear what role these gene mutations play in development of the condition.

Many people with essential thrombocythemia do not have a mutation in any of the known genes associated with this condition. Researchers are working to identify other genes that may be involved in the condition.

Read more about the JAK2, MPL, TET2, and THPO genes.

How do people inherit essential thrombocythemia?

Essential thrombocythemia can be inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. When it is inherited, the condition is called familial essential thrombocythemia.

Many cases of essential thrombocythemia are not inherited. Instead, the condition arises from gene mutations that occur after conception. This type of alteration is called a somatic mutation.

Where can I find information about diagnosis or management of essential thrombocythemia?

These resources address the diagnosis or management of essential thrombocythemia and may include treatment providers.

You might also find information on the diagnosis or management of essential thrombocythemia in Educational resources and Patient support.

General information about the diagnosis and management of genetic conditions is available in the Handbook. Read more about genetic testing, particularly the difference between clinical tests and research tests.

To locate a healthcare provider, see How can I find a genetics professional in my area? in the Handbook.

Where can I find additional information about essential thrombocythemia?

You may find the following resources about essential thrombocythemia helpful. These materials are written for the general public.

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

What other names do people use for essential thrombocythemia?

  • essential thrombocytosis
  • primary thrombocythemia
  • primary thrombocytosis

For more information about naming genetic conditions, see the Genetics Home Reference Condition Naming Guidelines and How are genetic conditions and genes named? in the Handbook.

What if I still have specific questions about essential thrombocythemia?

Where can I find general information about genetic conditions?

What glossary definitions help with understanding essential thrombocythemia?

References (8 links)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? in the Handbook.

 
Reviewed: December 2011
Published: September 15, 2014